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Note – an update
■ This presentation is an updated and expanded version of the 2016 presentation
■ This version was created as part of the fourth year scholarly project in medicine, and 
what was presented at the January 2018 University of Vermont Medical Center 
Family Medicine Grand Rounds
Why are we talking about Sex-Positivity?
■ Medical training so focused on “prevention” and “risk”
– This is NOT how people live their lives
■ May be awkward for some – why do we keep using language that makes this worse?
■ Research demonstrates patients have tremendous willingness / desire to speak about sexual health / 
function, but are unlikely to initiate discussions
– Docs also don’t initiate discussions
■ Med students and clinicians good at taking sexual history when the CC is directly related, but fail to 
opportunistically do so
Ultimately:
■ Sexual health related outcomes are not improving (STIs, HIV, unplanned/teenage pregnancy, 
preventative screening)
■ Patients don’t feel they are adequately attended to re: sexual health and function
– “Pleasure gap” for women
■ For “sexual minorities” (i.e. LGBT), sex positivity is critical to trust and therapeutic relationship
■ Our clinicians should be our advocates – more than anyone else – but we aren’t having discussions
– Discomfort? Lack of familiarity? General sex-shaming culture? 
What is “Sex Positivity”
■ Do we really think people avoid sex in order to 
minimize their risk of STIs or pregnancy?
– So why does our healthcare approach it 
this way?
“An attitude towards human sexuality that regards all consensual 
sexual activities as fundamentally healthy and potentially 
pleasurable, encouraging sexual pleasure and experimentation. 
The movement advocates sex education and safer sex, but 
generally makes no moral distinctions among types of sexual 
activities, regarding these choices as matters of personal 
preference” 
“ Too often sex is presented to our youth as something abnormal, 
immoral, and “other”, and when it finally rears its head, it does 
so often in unhealthy, irresponsible, and uninformed fashions”
How a sex-negative culture impacted me 
while trying to get on PrEP
■ Initial encounter
■ Subsequent encounter: clinical trials, 
CDC guidelines 
■ Pass the buck  bounce around
■ Avoidance of discussion
– Discomfort?
– Personal bias re: medicine?
■ Finally referred to Infectious Disease
– How this feels
■ No sexual history taken
■ No site-specific STI testing
■ Feeling uncomfortable with my provider
– Would I truly want to disclose more?
– Sense of being judged
The experiences of others here in VT
■ Similar “pass the buck”
■ Similar referral to ID
■ Docs willing to continue 
PrEP but not initiate it
■ “You’re sure you don’t 
have HIV?”
■ Assumption about being 
married, therefore, 
monogamous
– Burdens patient to feel 
obligated to disclose 
more information to get 
doc on board to test 
STIs
So what’s the big deal?
■ Sex is incredibly loaded with emotions: intimacy, vulnerability, pleasure, +/- pain, 
“coming of age”, +/- love and security. At times, negative associations for some.
■ Even more loaded for the LGBT community … “sexual orientation” … it’s our core identity
– In particular, the gay community:
■ HIV/AIDS epidemic and inadequate/inappropriate response by gov’t
– “the gays deserve to die”
■ Core individual identity related to who you have sex with. Gay culture is a sexual culture
■ Sex linked to illegality, death, torture in many places
■ Previously related to mental disorder in DSM
■ Our lives are inherently political – filing taxes, estate protection, healthcare decisions, 
employment security
What’s the problem?
■ >1.2 million Americans are living with HIV and nearly 1 in 8 (12.8%) are unaware of their 
status. 
■ Nationally, incidence ~ 50,000 new infections per year 
– (MSM) population carrying the largest burden. 25% of new infections are among youth 
(13-24yo
– MSM represents about 4% of the total US population but accounted for 78% of new HIV 
infections among men in 2010. 
What’s the problem like in Vermont?
■ Over the past 10 years, new diagnoses range from 11-19 per year
■ VT Dept. of Health: 670 HIV+ Vermonters
– Estimated to be closer to 800 HIV+ individuals when 
including those who are likely unaware of their status. 
– 56% fall into the MSM population. 
■ In 2012, a pre-exposure prophylaxis (PrEP) medication, Truvada, 
was FDA approved for HIV prevention. Despite this and clear 
evidence of its prophylactic effect from multiple clinical trials, 
community and provider awareness remains limited in Vermont 
with a most recent estimate of only 9 providers, not including 
Planned Parenthood offices or student health, who have actively 
prescribed PrEP. 
Public Health Costs of HIV/AIDS
■ US 2016 federal budget request included $31.7 billion 
dollars for combined domestic and global HIV efforts, 
with domestic funding estimated at $25.3 billion. This 
represents a 3.1% increase from the 2015 federal 
budget.
– Largest portion is for health care services & 
treatment for HIV+ individuals ($18.5 billion) 
– Smallest portion is for domestic HIV prevention, 
totally $940 million, which has remained largely 
unchanged over the past 6 years in the federal 
budget. 
■ Estimated lifetime costs for a new, early diagnosis of 
HIV infection is $400,000. 
■ VT Medicaid annual coverage for 300 HIV/AIDS 
patients in 2011 exceeded $3.6 million dollars. 
What are the possible interventions?
■ HIV testing centers and linkage to care
■ Antiretroviral therapy
■ Prevention programs for HIV+ individuals and partners
■ Substance abuse treatment programs
■ Access to condoms and sterile syringes
– Despite many advances in the treatment and prevention of HIV infections, the incidence rate has 
remained consistently around 50,000 new infections per year.
– “Doctors and policy makers need to admit that 30 years of the ABC mantra – abstain, be faithful, 
and use condoms – has failed. Men generally hate condoms, their lovers usually give in, almost 
no one abstains, precious few stay faithful” –
■ Donald G McNeil, Jr is a New York Times science and health reporter who covers diseases of the world’s 
poor, including AIDS. 
■ Pre-exposure prophylaxis (PrEP)
What are the barriers to PrEP use in VT?
– Lack of training about PrEP
– Concerns about costs and insurance coverage
– Development of a treatment resistant HIV
– Will this lead to riskier sexual behaviors?
– Concerns about increasing rates of other STI’s 
(gonorrhea, syphilis)
– Open and honest sexual behavior conversations
– Stigma – “slut shaming” by physicians; “Truvada 
whores” in the communities
– Nearly half of providers consider themselves “not 
confident at all” about having an informed discussion 
with patients regarding PrEP





















■ Pre-exposure prophylaxis – differs from PEP (post-exposure prophylaxis)
■ FDA approved in 2012 for HIV prevention in HIV-negative individuals
■ Truvada (combination of two medications)
– Emtricitabine (Emtriva) and tenofovir (Viread)
– Nucleoside reverse transcriptase inhibitors
■ Preventing HIV viral enzyme from making more copies of itself
Does PrEP actually work?
■ The studies to date are rock solid (iPrEx study)
– 2,500 HIV-seronegative men & transgender women who have sex with men.
■ NEJM; Pre-exposure prophylaxis for HIV prevention in MSM, Jan. 2011
■ Participants who took Truvada daily, estimated protection was 99%
■ Participants who took it 4 days per week, estimated protection was 96%
■ Participants who took it 2 days per week, estimated protection was 76%
Detectable blood levels strongly correlated with the prophylactic effect
The big picture:
■ Estimated 1/4 of all sexually active MSM have indication for PrEP
– (2014 US Public Health Service; PrEP Clinical Practice Guideline)
■ Estimated 1/5 of IV Drug Users have indication for PrEP
■ Estimated 1/200 heterosexual sexually-active adults have an indication for PrEP
What about other at risk populations?
■ Heterosexual men and women in serodiscordant relationships
■ Partners PrEP Study
– Truvada vs. tenofovir vs. placebo in 4,500 participants in Kenya & Uganda
– Reduction of new infections by 73% (of those assigned to take Truvada)
– When the researchers measured blood levels of the medication, the reduction 
rate was 90% fewer new infection
■ What does this mean?
Adherence to taking this medication daily matters!
N Engl J Med 2012; 367:399-410 August 2, 2012 DOI: 
10.1056/NEJMoa1108524
Who else would benefit from PrEP?
■ Bangkok Tenofovir Study
– Truvada vs. placebo in 2,400 participants who reported intravenous drug use 
during the previous year
– Overall, Truvada demonstrated reduction in risk of HIV infection by 49%
– But, again, when researchers looked at the participants who were directly 
observed taking Truvada daily, they found that protection increased to 74%
Further studies evaluation Truvada’s effect on truly parenteral HIV acquisition
Follow-up Research
■ Kaiser Permanente SF Medical Center Study (September 2015)
– N=657 individuals started PrEP, 99% MSM population
– No new HIV diagnoses
■ 74% reported no change in number of sexual partners
– 15% decreased the number of partners; 11% increased
■ 41% reported decreased condom use; 56% unchanged (people already do what they want)
■ 30% diagnosed with an STI in first 6-months, 50% in 12-months
– Chlamydia (33%), gonorrhea (28%), syphilis (5.5%)
■ Limitations: no control group, study population in SF has baseline higher rates HIV / viral 
undetectability
At Risk Populations
■ The studies to date have demonstrated Truvada’s potential in helping reduce the 
rate of HIV infection in the following at risk populations
– Men who have sex with men (MSM)
– Heterosexual serodiscordant (magnetic) couples
– Intravenous drug users (IVDU)*
Important take away…
Compliance with this medication is crucial to its prophylactic effect!
How to get the word out about PrEP?
■ PCP and community awareness & education
■ The ID community is well aware of PrEP
– 2013 national survey of ID physicians demonstrated that 74% supported the 
use of PrEP, yet only 9% had actually prescribed it.
■ UVM practice so far has been “refer to ID” … let’s stop this
■ HIV-negative, or assumed to be, MSM have NO REASON to see an ID specialist. If 
they’re seeing anyone for healthcare, it’s their PCP.
– Within marginalized communities, word spreads quickly about which 
providers are open and “safe” to talk to. 


What are the side effects of PrEP?
■ Most people taking Truvada report no side effects.
■ Those that are reported are generally mild…
– Nausea (9%), headaches (5%), weight loss (2%) and increased serum creatinine (0.3%)
■ As with many medications, there is a risk of serious side effects:
– Lactic acidosis, hepatic/renal dysfunction, worsening of hepatitis B infection if stopped
■ Recommended labs every 3 months to monitor for: 
– HIV status, other STI’s, LFT’s, and serum BUN/Cr
Lab Tests and Evaluation
■ 1) HIV antibody test
– Confirm HIV (-) status before initiating, and every 3 months 
(ideally within the week before refilling Rx)
– Accomplish via serum HIV ELISA or rapid POC FDA approved 
fingerstick blood test
■ Do NOT use oral rapid tests in PrEP monitoring due to less sensitivity
■ Do NOT accept self-reported results or documented anonymous 
results
– If positive HIV antibody: follow normal procedure for confirmatory 
testing
– If acute infection suspected, must defer to HIV RNA test for acute 
exposure 
Reminder: Which HIV test?
■ General Screening: Fourth generation immunoassay (detects antibodies)
– If positive, reflex to HIV 1 / HIV 2 Differentiation
■ Confirms the fourth generation test, also gives info on type of virus if present
– If within “window period” and concern for acute HIV infection/exposure, order 
tests for direct viral detection
■ P25 antigen, HIV RNA
Lab Tests and Evaluation
■ 2) Renal Function
– Obtain serum Cr and eCrCl
■ Minimum eCrCl of 60ml/min
– Among HIV+ persons prescribed Truvada-containing regimens, decreases in renal function 
(eCrCl) have been documented. Occasional cases of acute renal failure in HIV+ individuals
– In HIV negative individuals, eCrCl may decrease initially, eventually returning to baseline
■ 3) test for active HVB/HCV infection
– MSM and IVDU at increased risk
– Tenofovir has activity against HBV, thus if pt stops med, reactivation of HBV  hepatic 
damage
■ 4) Consider bone density evaluation if pt may be at risk
■ 5) Serum and Site-specific STI testing 
– Oropharyngeal and anal swabs for GC / Chlamydia
– Urine GC/Chlamydia





■ Essentially, no 
harm in running all 
of these routinely 
q3months for 
simplicity’s sake. 
It’s all the same 
blood draw
Importance of the Sexual History and 
site-specific STD testing
■ Q3month visits provide regular opportunities with obtaining a sexual history
■ Importance of site-specific testing (2010 CDC STD guidelines for MSM screening)
– Urethral G/C if insertive intercourse in past year 
■ Usually urine sample will suffice for this
– Rectal G/C if receptive anal sex in past year 
– Pharyngeal G/C if receptive oral sex in past year
■ Anal Paps?
– NY State Dept. of Health recommends for HIV+ patients
– CDC/USPSTF/ACS do not recommend 
– Recommendations? HIV- patients = baseline, q2-3 years (however still being studied)
■ For all sexually active pts:
– Consider dx of bacterial STIs in past 6 months as evidence of potential HIV-
exposure sexual activity, therefore, risk
■ Alcohol use / abuse screening (especially before sexual activity)
■ Screening for use of non-injection drugs
– Amyl nitrite (“poppers”) – assoc’d w/ sexual encounter enhancement
■ Smooth muscle (sphincter) relaxation, vasodilation and reflexive tachycardia 
(sensation of “excitement”)
– Stimulants 
Having The Talk: Approach to Clinical Assessment of the 
Patient – Sexual HIV Acquisition Risk
Having The Talk: Approach to Clinical Assessment of the 
Patient – Sexual HIV Acquisition Risk
Sexual history taking:
- 76% of MSM surveyed in 2008 in 21 US cities reported a health care visit in the past year
- However, many providers don’t ask about (and pts don’t disclose) same-sex behaviors
- Language unique to MSM: “bottoming” vs. “topping”, “bareback”/”raw”
*** “Are you and your partner exclusive or open?” ***
- San Francisco State Univ “Gay Couples Study”: found 47% of gay relationships are open, 45% monogamous, 
and 8% disagreed about their categorization
- Married / partnered does not mean monogamous! Many seeking PrEP are married/partnered
Cost Concerns
■ Truvada is covered by nearly all major insurance in VT:
– VT Medicaid
– VT Blue Cross – Blue Shield
– Other private insurances
■ Gilead “Advancing Access” Copay Card
– https://www.gileadadvancingaccess.com/copay-coupon-card 
– Covers drug copay cost
■ U.S. residents
■ Available for each valid prescription, no other purchase necessary
■ Pt cannot be currently receiving other free drug assistance through Gilead patient 
assistance programs
■ Gilead Financial Assistance Card
It is rare for an individual to pay full out-of-pocket cost for PrEP -- especially in Vermont
HIV risk is not static throughout lifetime – “seasonality” 
of risk
Identification of high-risk people might be less helpful than identification of high-risk 
moments and the situations that cause them, for example:
- Leaving home
- Becoming an adult
- Coming out as a MSM
- Immigrating to a new city
- Ending a relationship
** Family Medicine again is perfectly poised to intervene **
PROUD study reported that unexpectedly high HIV incidence (9 infections per 100 
person-years) in men who asked for PrEP and who were asked to defer
- HIV incidence was 3x expected based on epidemiologic trends
- People at higher risk of HIV infection were more likely to seek PrEP services, stay in 
care, and be adherent = the motivation is already there
iPrEx study: Evidence that PrEP is a strong attractor for those entering into a “season of 
high exposure to HIV”
- Temporal variation in risk behavior
The Condom Conundrum
■ Many people do not like sex with condoms
– Diminished sensation – acknowledge impact on intimacy and privacy
– Increased anxiety and ED? Caused by condoms? ED treatments
– Poor fit and the “I only use Magnum” issue
– Tissue irritation – know your lube options
■ Many people who do want to use condoms and need help
– Encourage open conversation. Ask, if yes, ask again. If no, ask why not.
– Strategies to respond when partner protests condom use
– www.condomania.com and www.luckybloke.com




■ Campaign whose goal is to achieve zero new HIV infections in Vermont by 2020
– Average of 11-19 new diagnoses per year (over the past 5 years)
– “Vermont is in striking distance of becoming the first state ever to achieve this goal” –
VT Cares
■ PrEP is front and center
■ Major limitation? 
– Currently only 9 providers actively prescribing PrEP
– “Insufficient to fully demonstrate the public health impact PrEP can have”
■ Peter Jacobsen, Executive Director of VT Cares
What can be done to overcome these 
barriers?
■ Provider education about PrEP
– Indications (at risk populations)
– Provider role in monitoring patients on PrEP
– *** HAVE THE CONVERSATION ***
– Truvada is covered by Vermont Medicaid and Blue Cross-Blue Shield
■ Patient awareness, education, and counseling
– VT Cares: counseling services currently, plans to expand
PrEP Updates: The Regimen
■ Preferred regimen remains TDF-FTC (tenofovir DISOPROXIL fumarate – emtricitabine) = Truvada
– Counsel to still use condoms 1 week after initiating (anal sex), 21 days (vaginal)
■ New TAF (“Descovy” - tenofovir ALAFENAMIDE) form
– Decreased renal/bone toxicity; already used in treating HIV
– However, NOT indicated for prophylaxis (PrEP) due to conflicting reports about having lower 
anal mucosal levels vs TDF
– Large multinational trial is underway
PrEP Updates: The Dosing Schedule
■ Preferred / approved dosing schedule remains daily (protection depends on total drug levels in 
mucosa)
■ Alternative dosing regimens have been studied and show promise:
– IPERGAY Study: “Event-Driven” / “On-Demand” therapy
■ relative reduction of 86% in the risk of HIV-1 infection.
■ Loading dose 2 tabs, 24 hours before unprotected sex
■ 1 tab daily while sexually active, continued 2 days after sexual activity ends
– Discrete period of sex (i.e. going on a trip) = start daily PrEP 1 wk prior, continue until 1 
month after
■ Supported by pharmacokinetic data for predicting protective levels of intracellular Tenofovir
■ Not completely evaluated in trials
■ NOTE: alternate dosing regimens not yet approved by FDA
– Also not evaluated in heterosexual men/women and sub-daily dosing not recommended for 
women having vaginal sex due to longer time needed to achieve adequate vaginal mucosa
What does the future hold for PrEP?
■ Current research for new pharmaceutical options for PrEP:
– Maraviroc – daily pill
– Rilpivirine – monthly injection
– Dapivirine – vaginal ring, changed monthly
– Tenofovir (alone) – rectal/vaginal gel
■ Discussions about a Truvada injection, every 3 months.
– NYU survey demonstrated that 79% of young gay men would prefer this option 
over a daily pill
– Cornell University currently recruiting for clinical trail
The Take-Home
■ Truvada is SO much more than just a medication
■ HIV for the MSM community is SO much more than just a chronic disease
– Remember the historical context
– Remember how it’s in the back of all of our minds
■ Individuals coming to you asking for PrEP have already self-identified as higher-risk individuals
■ Prescribing PrEP is incredibly simple – literally just a 5-item checklist. Requires no nuanced 
clinical judgment
– No more excuse for “not being comfortable”
■ We need advocates, not judges
– Approach healthcare from a sex-positive, non-judgmental mindset
– “The Ethical Slut” by Dossie Easton and Janet Hardy
– Dan Savage: “Savage Lovecast”
■ Zero new HIV infections is ACHIEVABLE in Vermont
Clinician Resources
■ San Francisco AIDS Foundation video “Demystifying PrEP”:  
http://yourekascience.org/portfolio/demystifying-hiv-pre-exposure-prophylaxis/
■ CDC PrEP Line: 1-855-HIV-PREP (1-855-448-7737)
11:00 a.m. - 6:00 p.m. ET Monday through Friday
■ Laura Catoe, NP – UVMMC Infectious Disease outpatient clinic
■ UpToDate articles:
– “Patient evaluation and selection for HIV pre-exposure prophylaxis”
– “Administration of pre-exposure prophylaxis against HIV infection”
PLEASE TAKE A HANDOUT!
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